# Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

> **NCT07501052** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sam Chun Dang Pharm. Co. Ltd.** · enrollment: 33 (estimated)

## Conditions studied

- Neovascular (Wet) Age-Related Macular Degeneration
- Retinal Vein Occlusion
- Diabetic Macular Edema
- Diabetic Retinopathy

## Interventions

- **DRUG:** SCD411 0.05mL (2mg)

## Key facts

- **NCT ID:** NCT07501052
- **Lead sponsor:** Sam Chun Dang Pharm. Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-08
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07501052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07501052, "Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07501052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*